JD

Joris De Maeyer

Executive in Residence at Bioqube Ventures

Mechelen, Flemish Region

Overview 

Joris De Maeyer is an accomplished Executive in the Biotech and Venture Capital industries, currently serving as an Executive in Residence and Investment Director at Bioqube Ventures. With a Ph.D. from Ghent University and extensive experience in leadership roles at companies like Facio Therapies and Shire, he excels in driving drug discovery and development initiatives while also providing strategic guidance and mentorship to emerging ventures in the pharmaceutical and biotech sectors.

Work Experience 

Stealth Mode I&I Company

  • Chief Operations Officer - COO

    2024 - Current

Invigo Therapeutics

  • Founder

    2023

    Founder of a NewCo focused on muscle health within the cardiometabolic space, addressing conditions such as sarcopenic obesity.

BV

Bioqube Ventures

  • Executive in Residence

    2023

  • Investment Director

    2020 - 2023

  • Venture Coach

    2016 - 2020

AT

Anavo Therapeutics BV

  • Board Observer

    2021

LIFE of SCI

  • Managing Director - Life Science Consulting

    2013

Facio Therapies

  • Chief Executive Officer

    2021 - 2022

    Through various roles with increasing responsibilities, established and led the R&D organization, advancing a program from the development of a unique phenotypic screening platform to successful candidate selection, while contributing to securing over €20M in funding.

  • Acting Chief Executive Officer

    2021 - 2021

  • Chief Scientific Officer

    2019 - 2021

  • Director R&D

    2014 - 2019

S

Shire

  • Director Discovery

    2011 - 2013

    Led a team within the exploratory projects group, driving innovative strategies and contributing to early-stage program development. Led efforts to advance a program to clinical candidate selection, driving key decisions and collaborating across disciplines.

Movetis

  • Manager Drug Discovery & Development

    2007 - 2010

    Collaborated with cross-functional development teams, contributing to both discovery, early- and late-stage development through to successful registration.

J&

Johnson & Johnson

  • Scientist Drug Discovery

    2002 - 2006

  • Senior Associate Preclinical Development (GLP DMPK TOX QA)

    2001 - 2002

Johnson & Johnson is a healthcare provider, expertise in innovative medicine and MedTech for every patient & for everyone.

jnj.com
VM

Vlaamse Milieumaatschappij - VMM

  • Auditor Surface Water Monitoring Network

    2001 - 2001

    Temporary assignment.

Education 

Articles About Joris

Relevant Websites